39 results
Industry
Blank
PROJECT NUMBER • 2019-013
PROJECT STATUS:
COMPLETED

Modelling environmental changes and effects on wild-caught species in Queensland

This project studied environmental factors which may be influencing the recruitment, catchability or productivity of Snapper, Pearl Perch, and Spanner Crab stocks in Queensland. Two environmental variables: GSLA and Chl-a were found to have strong associations with either abundance or catchability...
ORGANISATION:
University of Queensland (UQ)
Industry

Vaccination for emergency and long-term control of nodavirus in Australian marine aquaculture

Project number: 2018-098
Project Status:
Completed
Budget expenditure: $567,695.00
Principal Investigator: Andrew C. Barnes
Organisation: University of Queensland (UQ)
Project start/end date: 28 Mar 2019 - 30 Jan 2023
Contact:
FRDC
SPECIES

Need

The grouper industry is new but growing in Australia with recent new private sector investment in the hatchery in Cairns. However, all current grow out is affected by nodavirus outbreaks which have been both acute and severe. Without a solution the industry will not be able to continue. Fortunately, nodavirus is preventable by vaccination and there is local capacity to produce. Whilst there is currently insufficient demand to allow a fully privately financed vaccine initiative, with an emergency vaccine put in place and a registration data pack established, the industry is predicted to grow to a point where vaccine production by the private sector will become self-sustaining. This project will deliver an emergency vaccine to assist farmers through 2018/2019 grow out. It will build capability in vaccination of grouper in the industry. Most importantly it will provide the efficacy data, optimisation and formulation data with documentation appropriate for future licensing of a vaccine for use in Australia.

Objectives

1. An emergency vaccine to prevent nodavirus in the Queensland grouper cohort for stocking in spring/summer 2018
2. A data pack suitable for registration of an optimally formulated nodavirus vaccine for Australia

Final report

ISBN: 978-1-74272-399-0
Authors: Rosemary Thwaite Minami Kawasaki Angus Li Kelly Condon Richard Knuckey Bradley Cherrie Mark White Matt Landos and Andrew C Barnes
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.
Final Report • 2023-02-01 • 18.85 MB
2018-098-DLD.pdf

Summary

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew Barnes from The University of Queensland, designed and built a recombinant protein subunit vaccine against the Betanodavirus and supplied the construct and production outline to Tréidlia BioVet Pty Ltd (Sydney) for manufacture in September 2018. Under direction from Dr Matt Landos and Dr James Fensham (Future Fisheries Veterinary Services) and with permission from Dr Richard Knuckey (General Manager, The Company One), juvenile grouper were vaccinated under a research permit from the Australian Pesticides and Veterinary Medicines Authority (APVMA) at The Company One (TCO) Cairns hatchery in October 2018, and shipped for grow-out at Rocky Point Aquaculture in December 2018, less than 6 months after concept discussion. Vaccination coincided with a reduction in the severity of outbreaks and from mid-2019 to 2022 the farm was free from nodavirus outbreaks. In summer 2022, a persistent low-level  outbreak was recorded at the farm in vaccinated fish, although again well below the mortality levels of the 2018 outbreak. In controlled laboratory challenge studies by Dr Kelly Condon at James Cook University, the vaccine has been shown to be >90% effective. Vaccinated juveniles have also been purchased by Noosa Ecomarine and the vaccine has also coincided with substantially reduced mortalities by nodavirus in their recirculating aquaculture facility.

Investigations into the toxicology of pectenotoxin 2 seco acid and 7-epi pectenotoxin 2 seco acid to aid in a health risk assessment for the consumption of shellfish contaminated with these diarrhetic shellfish toxins in Australia

Project number: 2001-258
Project Status:
Completed
Budget expenditure: $20,000.00
Principal Investigator: Glen Shaw
Organisation: University of Queensland (UQ)
Project start/end date: 28 Mar 2002 - 30 Mar 2003
Contact:
FRDC

Need

The need for the research lies in the fact that no guideline values exist for pectenotoxins in shellfish. To produce these guidelines toxicological data need to be produced and currently there is a lack of knowledge of the PTX metabolism and mechanisms of toxicity. There is currently no oral toxicology data on the PTX2- seco acids and thus their inpact on human health cannot be assessed. There have been no published works of their metabolism in mammals or humans, and their chronic effects on health are unknown. The clinical symptoms are non-specific to DSP poisoning and it is believed that cases of bacterial poisoning and DSP are mis-diagnosed due to lack of toxicological information.

The presence of pectenotoxins can impose significant economic burden on the shellfish industry. Clear toxicological data on pectenotoxins will be used to undertake a risk assessment of pectenotoxins to enable the shellfish industry and regulators to make informed decisions about the withdrawal of product from sale or closure of farms in the presence of pectenotoxins in shellfish.

Objectives

1. A comprehensive study has been undertaken in which the aims are to (i) develop a robust method for extraction, purification and quantification of pectenotoxins in shellfish, (ii) investigate the pathology caused by the pectenotoxins when ingested orally, (iii) investigate P450 metabolism of the purified PTXs with the use of microarray technology and (iv) conduct a health risk assessment for the consumption of seafood contaminated with pectenotoxins. This study will provide a greater understanding of the metabolism and mechanisms of toxicity for the PTXs and provide information useful in the clinical assessment of poisoned patients and also provide information to be used in the setting of guideline values for pectenotoxins in seafood.

Final report

Spatial arrangement of estuarine and coastal habitats and the implications for fisheries production and diversity

Project number: 2001-023
Project Status:
Completed
Budget expenditure: $414,451.00
Principal Investigator: Greg A. Skilleter
Organisation: University of Queensland (UQ)
Project start/end date: 29 Jan 2002 - 1 Mar 2008
Contact:
FRDC

Objectives

1. Develop appropriate methods for determining relationships between the spatial arrangement of estuarine habitats (habitat mosaics) and their biota including fish, crustaceans and molluscs and more sedentary epibenthos (eg comparing the fauna of isolated seagrass with that of seagrass close to mangroves).
2. Document patterns of abundance and diversity of fish and decapods in different habitat mosaics from degraded and relatively undisturbed areas of estuarine embayments, in tow latitudinally separated areas (Moreton Bay) and taking into account position within an embayment (eg western side versus eastern side versus southern side)
3. Increase our understanding of fisheries-habitat links using a combination of standardised survey methods in Queensland and make comparisons with the results obtained in Victoria using the same methods and gear types.
4. Identify the relative importance of different nearshore habitats for key fish and decapod species from recruitment to older life-history stages and compare these results with those obtained for similar species and trophic groups in Victoria.

Final report

ISBN: 978-0-646-48289-7
Author: Gregory Skilleter

The Third International Billfish Symposium

Project number: 2000-192
Project Status:
Completed
Budget expenditure: $36,704.55
Principal Investigator: John Glaister
Organisation: University of Queensland (UQ)
Project start/end date: 21 Apr 2001 - 9 Oct 2003
Contact:
FRDC

Need

The third international billfish symposium has been anticipated by the world's fisheries community since the previous two such meetings (1972,1988) were watersheds in the advancement of knowledge of these important fishes. There have been significant increases in the world's understanding of billfish species stock structure and population dynamics, and corresponding increases in concerns for some global stocks. The Australian populations of billfishes occur in waters off most States and are especially well represented in the region of the Great Barrier Reef. Much of this area has recently been declared to be of World Heritage value and magnificent arrangements for natural resources has been under considerable scrutiny from agencies and organisations not usually concerned with fisheries management. There is a need to examine the global status of our understanding of these fishes and the management regimes adopted throughout the world. Australia may benefit from such an understanding. The broadbill swordfish is in decline in parts of the northern hemisphere and remedial action is needed to protect these stocks. Again, Australia would benefit from an understanding of past and present management practices for this species.

Objectives

1. Organise the third international Billfish symposium.
2. Publish the proceedings of the symposium.
View Filter

Organisation